{"id":"https://openalex.org/W7220660752","doi":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275","title":"Oligonucleotide-based medicinal products: A review of current regulatory requirements for preclinical studies","display_name":"Oligonucleotide-based medicinal products: A review of current regulatory requirements for preclinical studies","publication_year":2026,"publication_date":"2026-10-05","ids":{"openalex":"https://openalex.org/W7220660752","doi":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275"},"language":"en","primary_location":{"id":"doi:10.30895/2221-996x-2026-26-3-262-275","doi":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275","is_oa":true,"landing_page_url":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275","pdf_url":"https://www.biopreparations.ru/jour/article/download/817/1307","source":{"id":"https://openalex.org/S4210169820","display_name":"Biological Products Prevention Diagnosis Treatment","issn_l":"2221-996X","issn":["2221-996X","2619-1156"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological Products. Prevention, Diagnosis, Treatment","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"diamond","oa_url":"https://www.biopreparations.ru/jour/article/download/817/1307","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068915467","display_name":"\u0413. \u041d. \u0415\u043d\u0433\u0430\u043b\u044b\u0447\u0435\u0432\u0430","orcid":"https://orcid.org/0000-0001-5121-0858","observed_orcids":["https://orcid.org/0000-0001-5121-0858"]},"institutions":[{"id":"https://openalex.org/I4405258012","display_name":"Federal State Budgetary Institution \u2018Scientific Centre for Expert Evaluation of Medicinal Products\u2019 of the Ministry of Health of the Russian Federation (SCEEMP)","ror":"https://ror.org/05xze5t06","country_code":"RU","type":"government","lineage":["https://openalex.org/I4210117042","https://openalex.org/I4405258012"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"G. N. Engalycheva","raw_affiliation_strings":["Scientific Centre for Expert Evaluation of Medicinal Products"],"raw_orcid":"https://orcid.org/0000-0001-5121-0858","affiliations":[{"raw_affiliation_string":"Scientific Centre for Expert Evaluation of Medicinal Products","institution_ids":["https://openalex.org/I4405258012"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089638701","display_name":"R. D. Syubaev","orcid":"https://orcid.org/0000-0002-6729-2349","observed_orcids":["https://orcid.org/0000-0002-6729-2349"]},"institutions":[{"id":"https://openalex.org/I4405258012","display_name":"Federal State Budgetary Institution \u2018Scientific Centre for Expert Evaluation of Medicinal Products\u2019 of the Ministry of Health of the Russian Federation (SCEEMP)","ror":"https://ror.org/05xze5t06","country_code":"RU","type":"government","lineage":["https://openalex.org/I4210117042","https://openalex.org/I4405258012"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"R. D. Syubaev","raw_affiliation_strings":["Scientific Centre for Expert Evaluation of Medicinal Products"],"raw_orcid":"https://orcid.org/0000-0002-6729-2349","affiliations":[{"raw_affiliation_string":"Scientific Centre for Expert Evaluation of Medicinal Products","institution_ids":["https://openalex.org/I4405258012"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001875547","display_name":"A. A. Berchatova","orcid":"https://orcid.org/0000-0003-1462-2911","observed_orcids":["https://orcid.org/0000-0003-1462-2911"]},"institutions":[{"id":"https://openalex.org/I4405258012","display_name":"Federal State Budgetary Institution \u2018Scientific Centre for Expert Evaluation of Medicinal Products\u2019 of the Ministry of Health of the Russian Federation (SCEEMP)","ror":"https://ror.org/05xze5t06","country_code":"RU","type":"government","lineage":["https://openalex.org/I4210117042","https://openalex.org/I4405258012"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"A. A. Berchatova","raw_affiliation_strings":["Scientific Centre for Expert Evaluation of Medicinal Products"],"raw_orcid":"https://orcid.org/0000-0003-1462-2911","affiliations":[{"raw_affiliation_string":"Scientific Centre for Expert Evaluation of Medicinal Products","institution_ids":["https://openalex.org/I4405258012"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027824353","display_name":"O. V. Astapova","orcid":"https://orcid.org/0000-0003-3089-8395","observed_orcids":["https://orcid.org/0000-0003-3089-8395"]},"institutions":[{"id":"https://openalex.org/I4405258012","display_name":"Federal State Budgetary Institution \u2018Scientific Centre for Expert Evaluation of Medicinal Products\u2019 of the Ministry of Health of the Russian Federation (SCEEMP)","ror":"https://ror.org/05xze5t06","country_code":"RU","type":"government","lineage":["https://openalex.org/I4210117042","https://openalex.org/I4405258012"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"O. V. Astapova","raw_affiliation_strings":["Scientific Centre for Expert Evaluation of Medicinal Products"],"raw_orcid":"https://orcid.org/0000-0003-3089-8395","affiliations":[{"raw_affiliation_string":"Scientific Centre for Expert Evaluation of Medicinal Products","institution_ids":["https://openalex.org/I4405258012"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071285557","display_name":"Dmitriy Vladimirovich Goryachev","orcid":"https://orcid.org/0000-0001-8583-2372","observed_orcids":["https://orcid.org/0000-0001-8583-2372"]},"institutions":[{"id":"https://openalex.org/I4405258012","display_name":"Federal State Budgetary Institution \u2018Scientific Centre for Expert Evaluation of Medicinal Products\u2019 of the Ministry of Health of the Russian Federation (SCEEMP)","ror":"https://ror.org/05xze5t06","country_code":"RU","type":"government","lineage":["https://openalex.org/I4210117042","https://openalex.org/I4405258012"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"D. V. Goryachev","raw_affiliation_strings":["Scientific Centre for Expert Evaluation of Medicinal Products"],"raw_orcid":"https://orcid.org/0000-0001-8583-2372","affiliations":[{"raw_affiliation_string":"Scientific Centre for Expert Evaluation of Medicinal Products","institution_ids":["https://openalex.org/I4405258012"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5023787037","display_name":"\u0412\u0430\u0434\u0438\u043c \u0410\u043d\u0430\u0442\u043e\u043b\u044c\u0435\u0432\u0438\u0447 \u041c\u0435\u0440\u043a\u0443\u043b\u043e\u0432","orcid":"https://orcid.org/0000-0003-4891-973X","observed_orcids":["https://orcid.org/0000-0003-4891-973X"]},"institutions":[{"id":"https://openalex.org/I4405258012","display_name":"Federal State Budgetary Institution \u2018Scientific Centre for Expert Evaluation of Medicinal Products\u2019 of the Ministry of Health of the Russian Federation (SCEEMP)","ror":"https://ror.org/05xze5t06","country_code":"RU","type":"government","lineage":["https://openalex.org/I4210117042","https://openalex.org/I4405258012"]}],"countries":["RU"],"is_corresponding":false,"raw_author_name":"V. A. Merkulov","raw_affiliation_strings":["Scientific Centre for Expert Evaluation of Medicinal Products"],"raw_orcid":"https://orcid.org/0000-0003-4891-973X","affiliations":[{"raw_affiliation_string":"Scientific Centre for Expert Evaluation of Medicinal Products","institution_ids":["https://openalex.org/I4405258012"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4405258012"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"3","first_page":"262","last_page":"275"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.7598000168800354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.7598000168800354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12281","display_name":"Animal testing and alternatives","score":0.06430000066757202,"subfield":{"id":"https://openalex.org/subfields/3404","display_name":"Small Animals"},"field":{"id":"https://openalex.org/fields/34","display_name":"Veterinary"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.03799999877810478,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oligonucleotides","display_name":"oligonucleotides","score":0.8930000066757202},{"id":"https://openalex.org/keywords/preclinical-safety-evaluation","display_name":"preclinical safety","score":0.8629999756813049},{"id":"https://openalex.org/keywords/regulatory-requirements","display_name":"regulatory requirements","score":0.8450000286102295},{"id":"https://openalex.org/keywords/antisense-oligonucleotides","display_name":"antisense oligonucleotides","score":0.9449999928474426},{"id":"https://openalex.org/keywords/sirna","display_name":"siRNA","score":0.8859999775886536},{"id":"https://openalex.org/keywords/aptamers","display_name":"aptamers","score":0.9980000257492065},{"id":"https://openalex.org/keywords/regulatory-harmonization","display_name":"regulatory harmonization","score":0.5419999957084656},{"id":"https://openalex.org/keywords/drug-development","display_name":"drug development","score":0.38199999928474426},{"id":"https://openalex.org/keywords/rna-targeted-therapeutics","display_name":"RNA-targeted therapeutics","score":0.5170000195503235},{"id":"https://openalex.org/keywords/chemical-modification","display_name":"chemical modification","score":0.4869999885559082},{"id":"https://openalex.org/keywords/drug-delivery","display_name":"drug delivery","score":0.6190000176429749}],"concepts":[{"id":"https://openalex.org/C129312508","wikidata":"https://www.wikidata.org/wiki/Q133686","display_name":"Oligonucleotide","level":3,"score":0.6489999890327454},{"id":"https://openalex.org/C22615655","wikidata":"https://www.wikidata.org/wiki/Q203221","display_name":"Small interfering RNA","level":4,"score":0.5144000053405762},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4966000020503998},{"id":"https://openalex.org/C2780182762","wikidata":"https://www.wikidata.org/wiki/Q1630279","display_name":"Guideline","level":2,"score":0.49639999866485596},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.4788999855518341},{"id":"https://openalex.org/C128972844","wikidata":"https://www.wikidata.org/wiki/Q418722","display_name":"Aptamer","level":2,"score":0.45719999074935913},{"id":"https://openalex.org/C2776957806","wikidata":"https://www.wikidata.org/wiki/Q4895105","display_name":"Interim","level":2,"score":0.45089998841285706},{"id":"https://openalex.org/C89611455","wikidata":"https://www.wikidata.org/wiki/Q6804646","display_name":"Mechanism (biology)","level":2,"score":0.44909998774528503},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4221999943256378},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.413100004196167},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.399399995803833},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.39329999685287476},{"id":"https://openalex.org/C108170787","wikidata":"https://www.wikidata.org/wiki/Q3951828","display_name":"Agency (philosophy)","level":2,"score":0.39089998602867126},{"id":"https://openalex.org/C67705224","wikidata":"https://www.wikidata.org/wiki/Q11053","display_name":"RNA","level":3,"score":0.3723999857902527},{"id":"https://openalex.org/C2776120743","wikidata":"https://www.wikidata.org/wiki/Q3271540","display_name":"Mechanism of action","level":3,"score":0.35190001130104065},{"id":"https://openalex.org/C3020792226","wikidata":"https://www.wikidata.org/wiki/Q1331083","display_name":"Human use","level":2,"score":0.3513999879360199},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.3449000120162964},{"id":"https://openalex.org/C2994543053","wikidata":"https://www.wikidata.org/wiki/Q7239206","display_name":"Preclinical testing","level":2,"score":0.33500000834465027},{"id":"https://openalex.org/C188198153","wikidata":"https://www.wikidata.org/wiki/Q1613840","display_name":"Limiting","level":2,"score":0.32679998874664307},{"id":"https://openalex.org/C2778917124","wikidata":"https://www.wikidata.org/wiki/Q7309705","display_name":"Regulatory science","level":2,"score":0.3215999901294708},{"id":"https://openalex.org/C2910001868","wikidata":"https://www.wikidata.org/wiki/Q458","display_name":"European union","level":2,"score":0.30720001459121704},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.30329999327659607},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.30070000886917114},{"id":"https://openalex.org/C2777589142","wikidata":"https://www.wikidata.org/wiki/Q6770899","display_name":"Marketing authorization","level":2,"score":0.2888999879360199},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.2680000066757202},{"id":"https://openalex.org/C182306322","wikidata":"https://www.wikidata.org/wiki/Q1779371","display_name":"Order (exchange)","level":2,"score":0.2574999928474426},{"id":"https://openalex.org/C2989108626","wikidata":"https://www.wikidata.org/wiki/Q904407","display_name":"Drug target","level":2,"score":0.25040000677108765}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.30895/2221-996x-2026-26-3-262-275","doi":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275","is_oa":true,"landing_page_url":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275","pdf_url":"https://www.biopreparations.ru/jour/article/download/817/1307","source":{"id":"https://openalex.org/S4210169820","display_name":"Biological Products Prevention Diagnosis Treatment","issn_l":"2221-996X","issn":["2221-996X","2619-1156"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological Products. Prevention, Diagnosis, Treatment","raw_type":"journal-article"},{"id":"pmh:https://cyberleninka.ru/article/n/lekarstvennye-preparaty-na-osnove-oligonukleotidov-obzor-sovremennyh-regulyatornyh-trebovaniy-k-doklinicheskim-issledovaniyam","doi":null,"is_oa":true,"landing_page_url":"https://cyberleninka.ru/article/n/lekarstvennye-preparaty-na-osnove-oligonukleotidov-obzor-sovremennyh-regulyatornyh-trebovaniy-k-doklinicheskim-issledovaniyam","pdf_url":"https://cyberleninka.ru/article/n/lekarstvennye-preparaty-na-osnove-oligonukleotidov-obzor-sovremennyh-regulyatornyh-trebovaniy-k-doklinicheskim-issledovaniyam/pdf","source":{"id":"https://openalex.org/S4306401404","display_name":"CyberLeninK (CyberLeninka)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"text"},{"id":"pmh:oai:doaj.org/article:250661b1d95940e7bfe7b18e481e06b4","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/250661b1d95940e7bfe7b18e481e06b4","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"\u0411\u0438\u043e\u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u044b: \u041f\u0440\u043e\u0444\u0438\u043b\u0430\u043a\u0442\u0438\u043a\u0430, \u0434\u0438\u0430\u0433\u043d\u043e\u0441\u0442\u0438\u043a\u0430, \u043b\u0435\u0447\u0435\u043d\u0438\u0435, Vol 26, Iss 3, Pp 262-275 (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.30895/2221-996x-2026-26-3-262-275","doi":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275","is_oa":true,"landing_page_url":"https://doi.org/10.30895/2221-996x-2026-26-3-262-275","pdf_url":"https://www.biopreparations.ru/jour/article/download/817/1307","source":{"id":"https://openalex.org/S4210169820","display_name":"Biological Products Prevention Diagnosis Treatment","issn_l":"2221-996X","issn":["2221-996X","2619-1156"],"is_oa":true,"is_in_doaj":true,"is_core":false,"listed_in":["doaj","russia-white-list-2"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Biological Products. Prevention, Diagnosis, Treatment","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.8371999859809875,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320329807","display_name":"Ministry of Health of the Russian Federation","ror":"https://ror.org/01p8ehb87"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7220660752.pdf","grobid_xml":"https://content.openalex.org/works/W7220660752.grobid-xml"},"referenced_works_count":24,"referenced_works":["https://openalex.org/W1573075148","https://openalex.org/W2306449729","https://openalex.org/W2908697626","https://openalex.org/W3048788919","https://openalex.org/W3092810503","https://openalex.org/W3104685227","https://openalex.org/W3124395291","https://openalex.org/W4313279519","https://openalex.org/W4318310984","https://openalex.org/W4362518861","https://openalex.org/W4385588664","https://openalex.org/W4385932858","https://openalex.org/W4387100063","https://openalex.org/W4388731284","https://openalex.org/W4394728090","https://openalex.org/W4400562289","https://openalex.org/W4404798308","https://openalex.org/W4408266445","https://openalex.org/W4415044996","https://openalex.org/W4416528227","https://openalex.org/W4416770261","https://openalex.org/W7125402451","https://openalex.org/W7134951311","https://openalex.org/W7161706564"],"related_works":["https://openalex.org/W4245750749","https://openalex.org/W39222573","https://openalex.org/W2759673493","https://openalex.org/W4416528227","https://openalex.org/W3110703912","https://openalex.org/W3047301095","https://openalex.org/W4416770261","https://openalex.org/W4401388556","https://openalex.org/W2626352507","https://openalex.org/W3203058463"],"abstract_inverted_index":{"INTRODUCTION.":[0],"Oligonucleotides":[1,75,132],"represent":[2,76],"a":[3,26,31,288,303,322,332],"promising":[4],"class":[5,79],"of":[6,15,25,50,71,80,84,95,105,113,137,154,167,204,237,276,287,294,309,350,363],"drugs":[7,173],"with":[8,258],"unique":[9],"physicochemical":[10],"properties,":[11],"pharmacokinetic":[12],"characteristics,":[13],"mechanisms":[14],"action,":[16,96,138,351],"and":[17,30,59,61,93,169,181,189,210,218,222,313,338,354],"encouraging":[18],"therapeutic":[19,72],"potential.":[20],"Due":[21],"to":[22,67,120,124,234,330],"the":[23,36,46,68,110,150,200,208,215,223,235,238,259,265,269,274,285,291,307,359],"lack":[24],"national":[27],"Russian":[28,266],"guideline":[29,32,289],"currently":[33,250],"effective":[34],"within":[35],"Eurasian":[37],"Economic":[38],"Union":[39],"(EAEU),":[40],"existing":[41],"international":[42,254],"regulatory":[43,57],"requirements":[44],"for":[45,199,243,268,279,290,346],"preclinical":[47,69,201,292,340],"safety":[48,202],"assessment":[49,203],"oligonucleotides":[51,106,205,295,301],"were":[52],"reviewed.":[53],"AIM.":[54],"To":[55],"analyze":[56],"documents":[58],"scientific":[60,325,356],"methodological":[62],"sources":[63],"addressing":[64],"current":[65,355],"approaches":[66],"development":[70,286,320],"oligonucleotides.":[73],"DISCUSSION.":[74],"an":[77,175,230],"established":[78],"medicinal":[81],"products":[82],"consisting":[83],"chemically":[85],"synthesized":[86],"compounds":[87],"that":[88],"are":[89,191],"polymorphic":[90],"in":[91,194,264],"structure":[92],"mechanism":[94,136,349],"possessing":[97],"highly":[98,314],"specific":[99,111,315],"pharmacological":[100,103],"activity.":[101],"The":[102],"action":[104],"is":[107,249,296,321,328],"based":[108],"on":[109],"binding":[112],"synthetically":[114],"modified":[115],"RNA":[116,122,126],"or":[117,152,163],"RNA/DNA":[118],"hybrids":[119],"target":[121,168],"sequences":[123],"alter":[125],"expression":[127],"and/or":[128],"subsequent":[129],"protein":[130],"expression.":[131],"can":[133],"vary":[134],"by":[135,149,207,253],"structure,":[139],"chemical":[140,311,347],"modifications,":[141],"size,":[142],"sequence,":[143],"delivery":[144,352],"strategy,":[145],"as":[146,148,159,229],"well":[147],"presence":[151],"absence":[153],"other":[155],"functional":[156],"groups,":[157],"such":[158],"small":[160,179,186,310],"molecules,":[161],"proteins,":[162],"antibodies.":[164],"In":[165,256],"terms":[166],"species":[170],"specificity,":[171],"these":[172],"occupy":[174],"intermediate":[176],"position":[177],"between":[178],"molecules":[180,312],"biologics.":[182],"Currently,":[183],"antisense":[184],"oligonucleotides,":[185,284],"interfering":[187],"RNAs,":[188],"aptamers":[190],"successfully":[192],"utilized":[193],"clinical":[195],"practice.":[196],"Local":[197],"guidelines":[198],"proposed":[206],"Pharmaceuticals":[209],"Medical":[211],"Devices":[212],"Agency":[213,226],"(PMDA),":[214],"US":[216],"Food":[217],"Drug":[219],"Administration":[220],"(FDA),":[221],"European":[224],"Medicines":[225],"(EMA)":[227],"serve":[228],"interim":[231],"step":[232],"prior":[233],"release":[236],"globally":[239],"harmonized":[240],"International":[241],"Council":[242],"Harmonisation":[244],"(ICH)":[245],"S13":[246],"guideline,":[247],"which":[248,272],"being":[251],"developed":[252],"regulators.":[255],"accordance":[257],"Fundamental":[260],"Scientific":[261],"Research":[262],"Program":[263],"Federation":[267],"2021\u20132030":[270],"period,":[271],"states":[273],"goal":[275],"creating":[277],"technologies":[278],"silencing":[280],"damaged":[281],"genes":[282],"using":[283],"studies":[293],"considered":[297],"appropriate.":[298],"CONCLUSIONS.":[299],"Therapeutic":[300],"have":[302],"dual":[304],"nature,":[305],"combining":[306],"characteristics":[308],"biotechnological":[316],"products.":[317],"Since":[318],"oligonucleotide":[319],"dynamically":[323],"evolving":[324],"field,":[326],"it":[327],"advisable":[329],"utilize":[331],"flexible,":[333],"case-by-case":[334],"approach":[335,343],"when":[336],"planning":[337],"conducting":[339],"studies.":[341],"This":[342],"should":[344],"account":[345],"modification,":[348],"method,":[353],"knowledge":[357],"regarding":[358],"potential":[360],"toxic":[361],"effects":[362],"this":[364],"drug":[365],"class.":[366]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2026-10-07T00:00:00"}